ZYFLO CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYFLO CR is an extended-release oral tablet approved in 2007 by Chiesi for an undisclosed indication. The drug's mechanism of action and specific therapeutic area remain proprietary or insufficiently documented in available sources.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 score), signaling potential team restructuring or transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYFLO CR currently has zero linked job openings, reflecting its mature, declining lifecycle stage. Career opportunities on this product are limited, with roles primarily focused on maximizing value through market access and managed decline rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on ZYFLO CR at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.